161 related articles for article (PubMed ID: 21823839)
1. Teratogenicity of angiotensin converting enzyme inhibitors or receptor blockers.
Walfisch A; Al-maawali A; Moretti ME; Nickel C; Koren G
J Obstet Gynaecol; 2011 Aug; 31(6):465-72. PubMed ID: 21823839
[TBL] [Abstract][Full Text] [Related]
2. Major congenital malformations after first-trimester exposure to ACE inhibitors.
Cooper WO; Hernandez-Diaz S; Arbogast PG; Dudley JA; Dyer S; Gideon PS; Hall K; Ray WA
N Engl J Med; 2006 Jun; 354(23):2443-51. PubMed ID: 16760444
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin II-receptor-antagonists: further evidence of fetotoxicity but not teratogenicity.
Schaefer C
Birth Defects Res A Clin Mol Teratol; 2003 Aug; 67(8):591-4. PubMed ID: 14632309
[TBL] [Abstract][Full Text] [Related]
4. Clinical implications of increased congenital malformations after first trimester exposures to angiotensin-converting enzyme inhibitors.
Cooper WO
J Cardiovasc Nurs; 2008; 23(1):20-4. PubMed ID: 18158502
[TBL] [Abstract][Full Text] [Related]
5. Pregnancy outcome after in utero exposure to angiotensin converting enzyme inhibitors or angiotensin receptor blockers.
Diav-Citrin O; Shechtman S; Halberstadt Y; Finkel-Pekarsky V; Wajnberg R; Arnon J; Di Gianantonio E; Clementi M; Ornoy A
Reprod Toxicol; 2011 May; 31(4):540-5. PubMed ID: 21338666
[TBL] [Abstract][Full Text] [Related]
6. Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotensin receptor antagonists.
Quan A
Early Hum Dev; 2006 Jan; 82(1):23-8. PubMed ID: 16427219
[TBL] [Abstract][Full Text] [Related]
7. Increased risk of major congenital malformations in early pregnancy use of angiotensin-converting-enzyme inhibitors and angiotensin-receptor-blockers: a meta-analysis.
Fu J; Tomlinson G; Feig DS
Diabetes Metab Res Rev; 2021 Nov; 37(8):e3453. PubMed ID: 33779043
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in women of childbearing age: risks versus benefits.
Pucci M; Sarween N; Knox E; Lipkin G; Martin U
Expert Rev Clin Pharmacol; 2015 Mar; 8(2):221-31. PubMed ID: 25612630
[TBL] [Abstract][Full Text] [Related]
9. [The use of angiotensin converting enzyme (ACE) inhibitors during pregnancy clearly increases the risk of congenital malformations].
de Leeuw PW
Ned Tijdschr Geneeskd; 2006 Jul; 150(29):1605-7. PubMed ID: 16901062
[TBL] [Abstract][Full Text] [Related]
10. Is there an embryopathy associated with first-trimester exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists? A critical review of the evidence.
Polifka JE
Birth Defects Res A Clin Mol Teratol; 2012 Aug; 94(8):576-98. PubMed ID: 22807387
[TBL] [Abstract][Full Text] [Related]
11. Adverse pregnancy outcomes associated with maternal enalapril antihypertensive treatment.
Tabacova S; Little R; Tsong Y; Vega A; Kimmel CA
Pharmacoepidemiol Drug Saf; 2003 Dec; 12(8):633-46. PubMed ID: 14762979
[TBL] [Abstract][Full Text] [Related]
12. ACE inhibitors and major congenital malformations.
Sealey JE; Itskovitz-Eldor J
N Engl J Med; 2006 Sep; 355(12):1280-1; author reply 1281. PubMed ID: 16990393
[No Abstract] [Full Text] [Related]
13. Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and risk of malformations in offspring: a retrospective cohort study.
Li DK; Yang C; Andrade S; Tavares V; Ferber JR
BMJ; 2011 Oct; 343():d5931. PubMed ID: 22010128
[TBL] [Abstract][Full Text] [Related]
14. ACE inhibitors and congenital anomalies.
Friedman JM
N Engl J Med; 2006 Jun; 354(23):2498-500. PubMed ID: 16760451
[No Abstract] [Full Text] [Related]
15. Adverse pregnancy outcomes associated with first-trimester exposure to angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers: A systematic review and meta-analysis.
Buawangpong N; Teekachunhatean S; Koonrungsesomboon N
Pharmacol Res Perspect; 2020 Oct; 8(5):e00644. PubMed ID: 32815286
[TBL] [Abstract][Full Text] [Related]
16. ACE inhibitors and major congenital malformations.
Scialli AR; Lione A
N Engl J Med; 2006 Sep; 355(12):1280; author reply 1281. PubMed ID: 16998965
[No Abstract] [Full Text] [Related]
17. [Teratogenic effects of ACE-inhibitors and angiotensin II receptor antagonists].
Sørensen AM; Christensen S; Jonassen TE; Andersen D; Petersen JS
Ugeskr Laeger; 1998 Mar; 160(10):1460-4. PubMed ID: 9520613
[TBL] [Abstract][Full Text] [Related]
18. [Inhibition of the renin angiotensin system in pregnancy and risk of fetal malformations].
Lonati C; Morganti A
Pediatr Med Chir; 2009; 31(3):137-9. PubMed ID: 19739495
[No Abstract] [Full Text] [Related]
19. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.
Reboldi G; Angeli F; Cavallini C; Gentile G; Mancia G; Verdecchia P
J Hypertens; 2008 Jul; 26(7):1282-9. PubMed ID: 18550998
[TBL] [Abstract][Full Text] [Related]
20. The role of angiotensin receptor blockers in patients with angiotensin-converting enzyme inhibitor-induced angioedema.
Beavers CJ; Dunn SP; Macaulay TE
Ann Pharmacother; 2011 Apr; 45(4):520-4. PubMed ID: 21427294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
